Cerecor raises $15 million in B round

Cerecor Inc. (Baltimore, Md.) raised $15 million in the first tranche of a planned $32 million series B round. New investors New Enterprise Associates; Apple Tree Partners; and MPM Capital led the tranche. Cerecor's CERC-301 is in Phase II testing as adjunctive therapy for major depressive disorder (MDD), with data expected by year end. Cerecor has exclusive, worldwide rights to develop and commercialize the small molecule NMDA receptor NR2B subtype ( GRIN2B; NR2B) antagonist from Merck & Co. Inc. (NYSE:MRK). ...